

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**TONGOUR SIMPSON HOLSCLOW & COONEY**

2. Address:

227 Massachusetts Avenue, NE Suite One, Washington, DC 20005-7211

3. Principal place of business (if different from line 2):

4. Contact Name: BRAD HOLSCLOW

Telephone: 2025447600

E-mail (optional): holsclaw@tongoursimpson.com

Senate ID #: 51478-75

House ID #: 34927003

7. Client Name:  Self

**SANOFI-AVENTIS U.S**

### TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30):  **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report:  => Termination Date: \_\_\_\_\_ 11. No Lobbying Activity:

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more:  => Income (nearest \$20,000): 60,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more:  => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only  
 **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
 **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

**LOBBYING ACTIVITY.**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

Issues related to importation/reimportation of prescription drugs in and the Labor HHS-Education Appropriations Act.

17. House(s) of Congress and Federal agencies contacted:

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HOLSCLOW, JOHN "BRAD"

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.  
sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

HR 3610, "Food and Drug Import Safety Act of 2007"; S. 242, HR 380, "Pharmaceutical Market Access and Drug Safety Act of 2007"; HR 2638, "Department of Homeland Security Appropriations Act, 2008"; H. AMDY 734 to HR 3161 and S1859 "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2008" (provisions related to importation of prescription pharmaceuticals, safety inspections of such products, and the adequacy to protect the American public

17. House(s) of Congress and Federal agencies contacted:

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HOLSCLOW, JOHN "BRAD"

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

Issues related to follow-on biologics, drug safety, importation/reimportation of prescription drugs, drug advertising, and the Citizen's Petition process, including such provisions in S1082 "The Food and Drug Administration Revitalization Act" and HR3580. "The Food and Drug Administration Amendment Act of 2007", and HR3610 "Food and Drug Safety Act of 2007"; HR 1038 "Access to Life-Saving Medicine Act" and S1695 "Biologics Price Competition and Innovation Act of 2007" All provisions.

17. House(s) of Congress and Federal agencies contacted:

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HOLSCLOW, JOHN "BRAD"

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.  
sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.

**LOBBYING ACTIVITY**

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

Issues and provisions related to the closure of the Medicare Part D donut hole and other improvements for beneficiaries of the Medicare program, and the Medicaid drug rebate, including such provisions in HR3162 "The Children's Health and Medicare Protection Act of 2007 and S1607, "The Children's Health Insurance Program Reauthorization Act of 2007." Coding and reimbursement or coverage issues for Medicare Part B products and Medicare Part D services, preventative health screenings

17. House(s) of Congress and Federal agencies contacted:

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HOLSCLOW, JOHN "BRAD"

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.  
sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.

Signature: ON FILE Date: Feb 13, 2008

Printed Name and Title: BRAD HOLSCLOW, PARTNER -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE      Date: Feb 13, 2008

Printed Name and Title: -